Table 1. Neutropenia and Febrile Neutropenia in AML Patients Treated With Venetoclax.

	Venetoclax + azacitidine (n = 283)	Venetoclax + LDAC (n = 142)	Venetoclax + decitabine (n = 31)a
Grade ≥ 3 neutropenia	42%	46%	42%b
Grade ≥ 3 febrile neutropenia	42%	32%	61%

Note.AML = acute myeloid leukemia; LDAC = low-dose cytarabine. Information from DiNardo et al. (2019, 2020); Wei et al. (2020).

^aGrade 3/4 events.

^bDecreased white blood cell count.